Molecular insight into how a heart failure drug in clinical trials works

It’s time patient consent forms came back full circle to a tool for patient education, rather than the waiver of liability they have become. The original purpose of the consent forms was for a surgeon or doctor to inform the patient of common or serious risks associated with the procedure to be performed. However, the

Full Post: Informed consent process has lost its educational value

Individuals who have persistent high blood pressure are at increased risks of a number of serious medical conditions, including heart failure.

One of the factors that contributes to such heart failure is thickening of the muscle wall of the heart. Such thickening (known as hypertrophy) is a compensatory response of the heart to the high blood pressure. A team of researchers at Johns Hopkins University, Baltimore, has provided new insight into both the signaling mechanisms by which high blood pressure leads to compensatory hypertrophy of the mouse heart and the molecular mechanisms by which a heart failure drug in clinical trials works.

In the study, which was led by Eiki Takimoto and David Kass, when mice lacking the protein RGS2 were manipulated such that they had persistent high blood pressure they developed hypertrophy of the muscle wall of the heart more rapidly than normal mice manipulated in the same way. Further, these mice went on to exhibit heart failure and died at a young age. Additional analysis indicated that a drug that prevents hypertrophy by targeting the protein PDE5 was less effective at preventing hypertrophy caused by high blood pressure in RGS2-deficient mice than in normal mice. These data have clinical implications, as they provide insight into the mechanism by which PDE5 inhibitors, which have recently entered clinical trials to treat a form of heart failure, work.


Johns Hopkins and other researchers report what is believed to be the first direct evidence in lab animals that the erectile dysfunction drug sildenafil amplifies the effects of a heart-protective protein. The team’s findings, to be published in the Journal of Clinical Investigation online Jan. 5, helps explain why sildenafil, more widely known as Viagra,

Full Post: Viagra may help protect heart from high blood pressure damage

Cowling et al. report how to build muscle mass with FHL1. The protein partners with and activates the transcription factor, NFATc1. Encouraging this partnership might provide a possible treatment for muscle wasting disorders. The article will appear in the December 15, 2008 issue of The Journal of Cell Biology (JCB). Mutations in ‘Four and

Full Post: How to build muscle mass with four and a half LIM domains 1

Dr Andrew Whitten, Dr Cy Jeffries and Professor Jill Trewhella, from the School of Molecular and Microbial Biosciences, University of Sydney, with Samantha Harris, from the University of California, USA, have the first data showing how a protein in heart muscle cells works to maintain regular heart function. The research, published in the Proceedings of

Full Post: First study showing how protein fine-tunes the heart

For the first time, researchers have found that a modified form of a naturally occurring protein, N-cadherin, could prevent blocked arteries.  Blocked arteries are a major cause of heart attacks and strokes. The thickening of the artery wall, which occurs due to the build-up of fat and cells in the artery wall leads to

Full Post: Protein could prevent blocked arteries

A new clinical trial suggests that long-term use of candesartan, a drug currently used to treat hypertension, may significantly reduce the symptoms of genetic heart disease. The related report by Penicka et al, “The effects of candesartan on left ventricular hypertrophy and function in non-obstructive hypertrophic cardiomyopathy: a pilot, randomized study,” appears in the January

Full Post: Candesartan shown to be safe new therapy for genetic heart disease